Matches in SemOpenAlex for { <https://semopenalex.org/work/W2299697851> ?p ?o ?g. }
- W2299697851 endingPage "819" @default.
- W2299697851 startingPage "808" @default.
- W2299697851 abstract "Purpose To report the clinical outcomes of head and neck reirradiation with proton therapy. Methods and Materials From 2004 to 2014, 61 patients received curative-intent proton reirradiation, primarily for disease involving skull base structures, at a median of 23 months from the most recent previous course of radiation. Most had squamous cell (52.5%) or adenoid cystic (16.4%) carcinoma. Salvage surgery before reirradiation was undertaken in 47.5%. Gross residual disease was present in 70.5%. For patients with microscopic residual disease, the median dose of reirradiation was 66 Gy (relative biological effectiveness), and for gross disease was 70.2 Gy (relative biological effectiveness). Concurrent chemotherapy was given in 27.9%. Results The median follow-up time was 15.2 months and was 28.7 months for patients remaining alive. The 2-year overall survival estimate was 32.7%, and the median overall survival was 16.5 months. The 2-year cumulative incidence of local failure with death as a competing risk was 19.7%; regional nodal failure, 3.3%; and distant metastases, 38.3%. On multivariable analysis, Karnofsky performance status ≤70%, the presence of a gastrostomy tube before reirradiation, and an increasing number of previous courses of radiation therapy were associated with a greater hazard ratio for death. A cutaneous primary tumor, gross residual disease, increasing gross tumor volume, and a lower radiation dose were associated with a greater hazard ratio for local failure. Grade ≥3 toxicities were seen in 14.7% acutely and 24.6% in the late setting, including 3 treatment-related deaths. Conclusions Reirradiation with proton therapy, with or without chemotherapy, provided reasonable locoregional disease control, toxicity profiles, and survival outcomes for an advanced-stage and heavily pretreated population. Additional data are needed to identify which patients are most likely to benefit from aggressive efforts to achieve local disease control and to evaluate the potential benefit of proton therapy relative to other modalities of reirradiation. To report the clinical outcomes of head and neck reirradiation with proton therapy. From 2004 to 2014, 61 patients received curative-intent proton reirradiation, primarily for disease involving skull base structures, at a median of 23 months from the most recent previous course of radiation. Most had squamous cell (52.5%) or adenoid cystic (16.4%) carcinoma. Salvage surgery before reirradiation was undertaken in 47.5%. Gross residual disease was present in 70.5%. For patients with microscopic residual disease, the median dose of reirradiation was 66 Gy (relative biological effectiveness), and for gross disease was 70.2 Gy (relative biological effectiveness). Concurrent chemotherapy was given in 27.9%. The median follow-up time was 15.2 months and was 28.7 months for patients remaining alive. The 2-year overall survival estimate was 32.7%, and the median overall survival was 16.5 months. The 2-year cumulative incidence of local failure with death as a competing risk was 19.7%; regional nodal failure, 3.3%; and distant metastases, 38.3%. On multivariable analysis, Karnofsky performance status ≤70%, the presence of a gastrostomy tube before reirradiation, and an increasing number of previous courses of radiation therapy were associated with a greater hazard ratio for death. A cutaneous primary tumor, gross residual disease, increasing gross tumor volume, and a lower radiation dose were associated with a greater hazard ratio for local failure. Grade ≥3 toxicities were seen in 14.7% acutely and 24.6% in the late setting, including 3 treatment-related deaths. Reirradiation with proton therapy, with or without chemotherapy, provided reasonable locoregional disease control, toxicity profiles, and survival outcomes for an advanced-stage and heavily pretreated population. Additional data are needed to identify which patients are most likely to benefit from aggressive efforts to achieve local disease control and to evaluate the potential benefit of proton therapy relative to other modalities of reirradiation." @default.
- W2299697851 created "2016-06-24" @default.
- W2299697851 creator A5012639427 @default.
- W2299697851 creator A5027711988 @default.
- W2299697851 creator A5038118142 @default.
- W2299697851 creator A5046214153 @default.
- W2299697851 creator A5072745336 @default.
- W2299697851 creator A5075410853 @default.
- W2299697851 creator A5086616055 @default.
- W2299697851 date "2016-11-01" @default.
- W2299697851 modified "2023-10-10" @default.
- W2299697851 title "Reirradiation of Recurrent and Second Primary Head and Neck Cancer With Proton Therapy" @default.
- W2299697851 cites W1957921655 @default.
- W2299697851 cites W1964168560 @default.
- W2299697851 cites W1976104376 @default.
- W2299697851 cites W1984654549 @default.
- W2299697851 cites W1988259057 @default.
- W2299697851 cites W1988936862 @default.
- W2299697851 cites W1990742201 @default.
- W2299697851 cites W2004929347 @default.
- W2299697851 cites W2010461578 @default.
- W2299697851 cites W2021819143 @default.
- W2299697851 cites W2022811452 @default.
- W2299697851 cites W2029162258 @default.
- W2299697851 cites W2030389627 @default.
- W2299697851 cites W2034232079 @default.
- W2299697851 cites W2038981426 @default.
- W2299697851 cites W2050332814 @default.
- W2299697851 cites W2051482360 @default.
- W2299697851 cites W2073231352 @default.
- W2299697851 cites W2083960546 @default.
- W2299697851 cites W2091970516 @default.
- W2299697851 cites W2095918783 @default.
- W2299697851 cites W2112511211 @default.
- W2299697851 cites W2112845420 @default.
- W2299697851 cites W2113193425 @default.
- W2299697851 cites W2117817889 @default.
- W2299697851 cites W2133145006 @default.
- W2299697851 cites W2147222393 @default.
- W2299697851 cites W2153439641 @default.
- W2299697851 cites W2157668359 @default.
- W2299697851 cites W2160657334 @default.
- W2299697851 cites W2287176614 @default.
- W2299697851 cites W2885771277 @default.
- W2299697851 cites W4245214678 @default.
- W2299697851 doi "https://doi.org/10.1016/j.ijrobp.2016.07.037" @default.
- W2299697851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27788954" @default.
- W2299697851 hasPublicationYear "2016" @default.
- W2299697851 type Work @default.
- W2299697851 sameAs 2299697851 @default.
- W2299697851 citedByCount "72" @default.
- W2299697851 countsByYear W22996978512017 @default.
- W2299697851 countsByYear W22996978512018 @default.
- W2299697851 countsByYear W22996978512019 @default.
- W2299697851 countsByYear W22996978512020 @default.
- W2299697851 countsByYear W22996978512021 @default.
- W2299697851 countsByYear W22996978512022 @default.
- W2299697851 countsByYear W22996978512023 @default.
- W2299697851 crossrefType "journal-article" @default.
- W2299697851 hasAuthorship W2299697851A5012639427 @default.
- W2299697851 hasAuthorship W2299697851A5027711988 @default.
- W2299697851 hasAuthorship W2299697851A5038118142 @default.
- W2299697851 hasAuthorship W2299697851A5046214153 @default.
- W2299697851 hasAuthorship W2299697851A5072745336 @default.
- W2299697851 hasAuthorship W2299697851A5075410853 @default.
- W2299697851 hasAuthorship W2299697851A5086616055 @default.
- W2299697851 hasConcept C126322002 @default.
- W2299697851 hasConcept C126838900 @default.
- W2299697851 hasConcept C141071460 @default.
- W2299697851 hasConcept C207103383 @default.
- W2299697851 hasConcept C2776530083 @default.
- W2299697851 hasConcept C2777546739 @default.
- W2299697851 hasConcept C2779231225 @default.
- W2299697851 hasConcept C2911091166 @default.
- W2299697851 hasConcept C44249647 @default.
- W2299697851 hasConcept C509974204 @default.
- W2299697851 hasConcept C71924100 @default.
- W2299697851 hasConcept C88879693 @default.
- W2299697851 hasConceptScore W2299697851C126322002 @default.
- W2299697851 hasConceptScore W2299697851C126838900 @default.
- W2299697851 hasConceptScore W2299697851C141071460 @default.
- W2299697851 hasConceptScore W2299697851C207103383 @default.
- W2299697851 hasConceptScore W2299697851C2776530083 @default.
- W2299697851 hasConceptScore W2299697851C2777546739 @default.
- W2299697851 hasConceptScore W2299697851C2779231225 @default.
- W2299697851 hasConceptScore W2299697851C2911091166 @default.
- W2299697851 hasConceptScore W2299697851C44249647 @default.
- W2299697851 hasConceptScore W2299697851C509974204 @default.
- W2299697851 hasConceptScore W2299697851C71924100 @default.
- W2299697851 hasConceptScore W2299697851C88879693 @default.
- W2299697851 hasIssue "4" @default.
- W2299697851 hasLocation W22996978511 @default.
- W2299697851 hasLocation W22996978512 @default.
- W2299697851 hasOpenAccess W2299697851 @default.
- W2299697851 hasPrimaryLocation W22996978511 @default.
- W2299697851 hasRelatedWork W2003938723 @default.
- W2299697851 hasRelatedWork W2047967234 @default.
- W2299697851 hasRelatedWork W2059159226 @default.